🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

NEWS FROM INDUSTRY: Source MERCK Update HERTHENA-Lung02 🫁 Daiichi Sankyo and Merck have voluntarily withdrawn their Biologics License Application seeking accelerated approval for patritumab deruxtecan (HER3-DXd) in the U.S. 🇺🇸for EGFR-mutated 🧬advanced non-small cell

And the fun starts! From @asco #asco25 press release Overall survival was 30.3 months in the encorafenib/cetuximab with mFOLFOX6 arm, 19.5 months in the encorafenib/cetuximab alone arm, and 15.1 months in the control arm. PFS pic below NEJM asco.org/about-asco/pre…

📌 Prostate CA Picks: Top 5 #ASCO25 Abstract #5000: CAN-2409 + EBRT ± ADT in Localized PrCa (#TheodoreDeWeeseMD) 🗓 Tue 3 Jun · 09:45 CDT Abstract #LBA5006: AMPLITUDE—Niraparib + AAP in mCSPC (#GerhardtAttardMD) 🗓 Sat 31 May · 13:15 CDT Abstract #5005: ARCHES 5-Year OS

One day before GU Talks start, here’s your GU Spotlight: 📌 My Top 5 Kidney Cancer #ASCO25 Abstracts Abstract #4505: CheckMate 214 Final—Nivo + Ipi vs Sunitinib (Robert Motzer MD) 🗓️ Sun 1 Jun · 11:33 CDT Abstract #4511: CheckMate 9ER Integrated Biomarkers (David Braun) 🗓️ Sun 1 Jun ·

The ASCO Ed Book is the highest-quality, peer-reviewed, free #oncology #MedEd ever. Whether or not you are attending #ASCO25, don’t miss out on this, #OncTwitter #MedTwitter, #MedStudentTwitter. Bookmark this tweet to keep the link handy: ascopubs.org/toc/edbk/curre… #OncoAlert

#ASCO25 Highlight: 5-year follow-up from #KEYNOTE564 showing sustained benefit of adjuvant pembrolizumab in clear cell #RCC. DFS: 60.9% vs 52.2%, OS: 87.7% vs 82.3% vs placebo. No new safety signals. SOC remains strong. #KidneyCancer #Immunotherapy. #ReadNow >

An inspiring #ASCO25 education session with Dr Joseph McCollom DO on finding your passion in oncology 💡 From embracing new paths to thoughtful self-assessment and work–life integration — a powerful reminder that purpose and opportunity often go hand in hand ASCO

Diagnostic and therapeutic advances are reshaping how we treat GU cancers — and Dr. Rana McKay, MD, FASCO is at the forefront of the conversation at #ASCO25 A dynamic education session spotlighting evolving paradigms and precision approaches in #GUonc ASCO

#Cancer de #bexiga e #urotelial alto. Mais análises de opção de tratamento na 1a linha. #accamargocancercenter

. Cristiane D Bergerot presenting her study Prognostic awareness among older adults w metastatic cancer in Brazil: GAIN-S, a telehealth geriatric intervention, improved patients’ emotional and adaptive responses. Telehealth works—especially for supportive care. #ASCO25 ASCO

#ASCO25 Final results of IO-based combinations in mRCC are in! See below and subsequent posts for thoughts. Video discussing these data coming soon from OncoAlert...

#accamargocancercenter Rachel Riechelmann

Acontece com muitos - e frequentemente.

Registration open at apccc.org! Everyone interested in the management of patients with advanced prostate cancer can participate! Hope to see you all there!

ICYMI from #ASC25: Yelena Y. Janjigian MD shared research from a clinical trial that demonstrated a powerful new approach to help prevent cancer from coming back after treatment for #stomachcancer and cancer of the lower portion of the esophagus and #esophagealjunction. Learn more about

📢 Just published in Journal of the @NCCN ! Our RCT shows that a telehealth GA & #SuppCare Intervention (GAIN-S) improved physical function, mood & QoL in older Brazilians with metastatic cancer William Dale, MD, PhD, FASCO Enrique Soto Areej El-Jawahri Ryan Nipp, MD, MPH, MBA, FASCO jnccn.org/view/journals/…

Thank you to all colleagues who voted in the 2025 #ESMO election I'm honored to announce that I was elected as Director of Membership 😊 my aim is to extend ESMO - Eur. Oncology benefits to much more members across the globe!

#accamargocancercenter #telemedicina #oncogeriatria SBOC SIOG Carlos Sacomani Gabriel